Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036?

This article examines whether an investment in Vertex Pharmaceuticals (VRTX) could turn $100,000 into $1 million by 2036, requiring an average annual growth rate of 26%. While Vertex has had strong market-beating returns in the past, its current size and the limited patient population for its cystic fibrosis drugs make it unlikely to achieve this aggressive growth through its existing pipeline alone. However, the article still recommends Vertex as a buy-and-hold stock due to its consistent revenue, earnings, and future diversified lineup from new drug approvals.